

Press Release

India Branded business up 17%

Net Profit Rs 176 crores

Vadodara, February 10th, 2022

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st December 2021.

Financial Highlights

- Net Sales for the quarter at Rs 1272 crores.
- Net Profit for the quarter at Rs 176 crores.
- Net sales for 9M FY22 at Rs 3890 crores.
- Net profit for 9M FY22 at Rs 510 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded business has posted a strong growth rate for the third consecutive quarter. Strong operational performance is attributed to consistent efforts of team and strengthening of customer relationships. Branded business witnessed market outperforming growth across most of the key products and therapy areas."

Operational Highlights

International Generics

- US Generics at Rs 393 crores in the quarter and at Rs 1109 Crores for 9M FY22.
- Ex-US International Formulations at Rs 193 Crores in the quarter and at Rs 587 Crores for 9M FY22.
- 6 ANDA filings during the quarter; Cumulative ANDA filings at 220.
- 4 ANDA approvals received during the quarter including 2 tentative; 154 Cumulative ANDA approvals including 20 tentative.

India Branded


- India Branded Business at Rs 488 crores in the quarter and at Rs 1478 crores in the 9M FY22.
- Acute & specialty segment grew faster than IPM.

API

- API business at Rs 198 crores in the quarter and at Rs 716 crores for 9M FY22.
- 1 DMF was filed in the quarter.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880. • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY22	Q3 FY21	% Change	9M FY22	9M FY21	% Change
Formulation						
USA	393	512	(23%)	1109	1689	(34%)
Ex-US	193	171	13%	587	544	8%
India	488	418	17%	1478	1138	30%
API	198	214	(7%)	716	741	(3%)
Total	1272	1314	(3%)	3890	4113	(5%)

Summary of Profit is as under:

(Rs in Crores)

Particulars	Q3 FY22	Q3 FY21	% Change	9M FY22	9M FY21	% Change
EBITDA Pre R&D	406	536	(24%)	1233	1713	(28%)
<i>EBITDA Pre R&D %</i>	32%	41%		32%	42%	
EBITDA Post R&D	269	401	(33%)	791	1272	(38%)
<i>EBITDA Post R&D %</i>	21%	31%		20%	31%	
Profit Before Tax	209	352	(41%)	616	1126	(45%)
Net Profit after Tax	176	293	(40%)	510	927	(45%)



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123


About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 6637630 Email: mitanshu.shah@alembic.co.in
---	---



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123